

August 9, 2022



# Kiora Pharmaceuticals To Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference; Online Presentation Will Be Available August 17, 2022 at 7:00 am EST

Salt Lake City, Utah--(August 9, 2022) - [Kiora Pharmaceuticals, Inc.](#) (NASDAQ: KPRX), ("Kiora" or the "Company") today announced it will participate in the [H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference](#).

The Company's presentation will be available on-demand from the [Investor Relations section](#) of Kiora's website (<https://ir.kiorapharma.com>) on August 17, 2022, starting at 7:00 am Eastern Daylight Time. The presentation will be archived on the Kiora's website for 90 days.

## About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid Arthritis ("OPRA"). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase ("DHODH") with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.

In addition to news releases and SEC filings, we expect to post information on our website, [www.kiorapharma.com](http://www.kiorapharma.com), and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.

**Investor Contact**

Francina Agosti, PhD

(617) 546-0742

[fagosti@reportablenews.com](mailto:fagosti@reportablenews.com)